索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]陈建林,孟婷婷,张钰,等.虾青素在心血管疾病中的作用[J].国际心血管病杂志,2024,04:216-219,223.
点击复制

虾青素在心血管疾病中的作用(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年04期
页码:
216-219,223
栏目:
综述
出版日期:
2024-07-31

文章信息/Info

Title:
-
作者:
陈建林; 孟婷婷; 张钰; 郑燕; 苏国海
作者单位：261000 潍坊，山东第二医科大学临床医学院（陈建林）；250013 济南市中心医院心内科（孟婷婷，张钰，苏国海）、250013 济南，山东第一医科大学附属中心医院专科转化研究中心（郑燕）
Author(s):
-
关键词:
虾青素; 心血管疾病; 作用机制; 抗炎; 抗氧化
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.04.007
文献标识码:
-
摘要:
虾青素具有独特的抗氧化和抗炎特性，对高血压、冠状动脉粥样硬化性心脏病、心力衰竭、心肌梗死和心肌病有潜在治疗作用。该文介绍虾青素对心血管疾病的治疗效果及可能的分子机制，并结合临床研究讨论虾青素目前存在的问题。
Abstract:
-

参考文献/References

[1] 郑鑫鑫, 黄青. 天然虾青素清除超氧阴离子的抗氧化能力[J].食品研究与开发, 2023, 44(14):8-12, 162.
[2] Park JS, Chyun JH, Kim YK, et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans[J]. Nutr Metab (Lond), 2010, 7(1):18.
[3] Pereira CPM, Souza ACR, Vasconcelos AR, et al. Antioxidant and anti inflammatory mechanisms of action of astaxanthin in cardiovascular diseases(Review)[J]. Int J Mol Med, 2021(1):37-48.
[4] Kohandel Z, Farkhondeh T, Aschner M, et al. Anti-inflammatory action of astaxanthin and its use in the treatment of various diseases[J]. Biomed Pharmacother, 2022, 145:112179.
[5] Xue XL, Han XD, Li Y, et al. Astaxanthin attenuates total body irradiation-induced hematopoietic system injury in mice via inhibition of oxidative stress and apoptosis[J]. Stem Cell Res Ther, 2017, 8(1):7.
[6] Hormozi M, Ghoreishi S, Baharvand P. Astaxanthin induces apoptosis and increases activity of antioxidant enzymes in LS-180 cells[J]. Artif Cells Nanomed Biotechnol, 2019, 47(1):891-895.
[7] Hussein G, Nakamura M, Zhao Q, et al. Antihypertensive and neuroprotective effects of astaxanthin in experimental animals[J]. Biol Pharm Bull, 2005, 28(1):47-52.
[8] Preuss HG, Echard B, Yamashita E, et al. High dose astaxanthin lowers blood pressure and increases insulin sensitivity in rats: are these effects interdependent?[J]. Int J Med Sci, 2011, 8(2):126-138.
[9] Monroy-Ruiz J, Sevilla M?, Carrón R, et al. Astaxanthin-enriched-diet reduces blood pressure and improves cardiovascular parameters in spontaneously hypertensive rats[J]. Pharmacol Res, 2011, 63(1):44-50.
[10] Hatabu T, Harada T, Takao Y, et al. Daily meal supplemented with astaxanthin-enriched yolk has mitigative effects against hypertension in spontaneously hypertensive rats[J]. Biol Pharm Bull, 2020, 43(3):404-408.
[11] Chen YQ, Li S, Guo YX, et al. Astaxanthin attenuates hypertensive vascular remodeling by protecting vascular smooth muscle cells from oxidative stress-induced mitochondrial dysfunction[J]. Oxid Med Cell Longev, 2020, 2020:4629189.
[12] Gao HL, Yu XJ, Zhang Y, et al. Astaxanthin ameliorates blood pressure in salt-induced prehypertensive rats through ROS/MAPK/NF-κB pathways in the hypothalamic paraventricular nucleus[J]. Cardiovasc Toxicol, 2021, 21(12):1045-1057.
[13] Birudaraju D, Cherukuri L, Kinninger A, et al. A combined effect of cavacurcumin, eicosapentaenoic acid (omega-3s), astaxanthin and gamma -linoleic acid (omega-6) (ceag) in healthy volunteers-a randomized, double-blind, placebo-controlled study[J]. Clin Nutr ESPEN, 2020, 35:174-179.
[14] Spiller GA, Dewell A. Safety of an astaxanthin-rich Haematococcus pluvialis algal extract: a randomized clinical trial[J]. J Med Food, 2003, 6(1):51-56.
[15] Kishimoto Y, Yoshida H, Kondo K. Potential Anti-Atherosclerotic properties of astaxanthin[J]. Mar Drugs, 2016, 14(2):35.
[16] Iwamoto T, Hosoda K, Hirano R, et al. Inhibition of low-density lipoprotein oxidation by astaxanthin[J]. J Atheroscler Thromb, 2000, 7(4):216-222.
[17] Yoshida H, Yanai H, Ito K, et al. Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia[J]. Atherosclerosis, 2010, 209(2):520-523.
[18] Zuluaga M, Barzegari A, Letourneur D, et al. Oxidative stress regulation on endothelial cells by hydrophilic astaxanthin complex: chemical, biological, and molecular antioxidant activity evaluation[J]. Oxid Med Cell Longev, 2017:8073798.
[19] Ishiwata S, Kato T, Kasai T, et al. Changes in self-reported physical activity and health-related quality of Life following 3-month astaxanthin supplementation in patients with heart failure: results from a pilot study[J]. Ann Palliat Med, 2021, 10(2):1396-1403.
[20] Krestinina O, Baburina Y, Krestinin R. Mitochondrion as a target of astaxanthin therapy in heart failure[J]. Int J Mol Sci, 2021, 22(15):7964.
[21] Brasil FB, Bertolini Gobbo RC, Souza de Almeida FJ, et al. The signaling pathway PI3K/Akt/Nrf2/HO-1 plays a role in the mitochondrial protection promoted by astaxanthin in the SH-SY5Y cells exposed to Hydrogen peroxide[J]. Neurochem Int, 2021, 146:105024.
[22] Yu LL, Feng ZW. The role of Toll-like receptor signaling in the progression of heart failure[J]. Mediators Inflamm, 2018, 2018:9874109.
[23] Zaafan MA, Abdelhamid AM. The cardioprotective effect of astaxanthin against isoprenaline-induced myocardial injury in rats: involvement of TLR4/NF-κB signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2021, 25(11):4099-4105.
[24] Pan X, Zhang K, Shen C, et al. Astaxanthin promotes M2 macrophages and attenuates cardiac remodeling after myocardial infarction by suppression inflammation in rats[J]. Chin Med J (Engl), 2020, 133(15):1786-1797.
[25] Walton KL, Johnson KE, Harrison CA. Targeting TGF-β mediated SMAD signaling for the prevention of fibrosis[J]. Front Pharmacol, 2017, 8:461.
[26] Shi Y, Lin P, Wang XN, et al. Sphingomyelin phosphodiesterase 1 (SMPD1) mediates the attenuation of myocardial infarction-induced cardiac fibrosis by astaxanthin[J]. Biochem Biophys Res Commun, 2018, 503(2):637-643.
[27] Zhang J, Wang QZ, Zhao SH, et al. Astaxanthin attenuated pressure overload-induced cardiac dysfunction and myocardial fibrosis: partially by activating SIRT1[J]. Biochim Biophys Acta Gen Subj, 2017, 1861(7):1715-1728.
[28] 沈成, 王龙, 康文, 等. 虾青素对急性心梗大鼠心肌细胞凋亡及caspase-3表达的影响[J]. 山西医科大学学报, 2018, 49(7):749-753.
[29] Li H, Yin AW, Cheng ZJ, et al. Attenuation of Na/K-ATPase/Src/ROS amplification signal pathway with pNaktide ameliorates myocardial ischemia-reperfusion injury[J]. Int J Biol Macromol, 2018, 118(Pt A):1142-1148.
[30] Gao F, Zhao Y, Zhang B, et al. Mitochondrial targeted astaxanthin liposomes for myocardial ischemia-reperfusion injury based on oxidative stress[J]. J Biomater Appl, 2022, 37(2):303-314.
[31] Tuzlak S, Kaufmann T, Villunger A. Interrogating the relevance of mitochondrial apoptosis for vertebrate development and postnatal tissue homeostasis[J]. Genes Dev, 2016, 30(19):2133-2151.
[32] Wang WH, Liu TH, Liu YY, et al. Astaxanthin attenuates alcoholic cardiomyopathy via inhibition of endoplasmic reticulum stress-mediated cardiac apoptosis[J]. Toxicol Appl Pharmacol, 2021, 412:115378.
[33] Xie WJ, Hou G, Wang L, et al. Astaxanthin suppresses lipopolysaccharide-induced myocardial injury by regulating MAPK and PI3K/AKT/mTOR/GSK3β signaling[J]. Mol Med Rep, 2020, 22(4):3338-3346..
[34] Yang X, Guo AL, Pang YP, et al. Astaxanthin attenuates environmental tobacco smoke-induced cognitive deficits: a critical role of p38 MAPK[J]. Mar Drugs, 2019, 17(1):24.
[35] Chen L, Liu P, Feng X, et al. Salidroside suppressing LPS-induced myocardial injury by inhibiting ROS-mediated PI3K/Akt/mTOR pathway in vitro and in vivo[J]. J Cell Mol Med, 2017, 21(12):3178-3189.
[36] U.S. National Library of Medicine. Clinica lTrials[DB/OL]. [2023-09-20]. https://www.clinicaltrials.gov./study/NCT0164798 4?cond=NCT01647984&rank=1
[37] U.S. National Library of Medicine. Clinica lTrials[DB/OL]. [2023-09-20]. https://www.clinicaltrials.gov./study/NCT0208703 3?cond=NCT02087033&rank=1
[38] 孟豪杰, 潘丽, 刘彦君, 等. 虾青素的运载体系研究进展[J]. 河南工业大学学报(自然科学版), 2023, 44(5):125-132.
[39] EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA); Turck D, Castenmtler J, et al. Safety of astaxanthin for its use as a novel food in food supplements[J]. EFSA J, 2020, 18(2):e05993.

备注/Memo

备注/Memo:
基金项目：国家科技重大专项( 2020ZX09201025）；山东省自然科学基金面上项目（ZR2017MH050）
通信作者：苏国海， E-mail：gttstg@163.com
更新日期/Last Update: 2024-07-31